Given the key role of BAFF in B cell clonal expansion and lymphoma development [195], it seemed that targeting BAFF and CD20 simultaneously through belimumab/rituximab co-administration could represent a promising therapeutic approach in for MALT subtype of pSS [92]. This evidence concerns the gene TNFSF13B and peeling skin syndrome.